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Abstract
Recurrent acute sickle cell painful crises are the hallmark of sickle cell anemia. These
events may be mild, moderate or severe in nature and often require treatment at home,
in acute care facilities as outpatients, and in the hospital with oral and/or parenteral
opioids. The type, dose, route & frequency of administration of opioids, as well as the
length of hospital stay (LOS), are not well known for adults with sickle cell anemia (SS).
We analyzed these aspects in the 299 patients enrolled in the Multicenter Study of
Hydroxyurea (MSH) in SS. For these patients there were 16818 home diaries, 2249
acute care contacts, and 2209 hospitalizations. At home analgesics were used on 40%
of diary days and 80% of 2-week follow up periods, with oxycodone and codeine the
most frequently used. Responders to hydroxyurea (HU) used analgesics on fewer days.
During hospitalization 96% were treated with parenteral opioids, with meperidine the
most frequently used; oxycodone was the most commonly used oral medication. The
average LOS for responders to HU was about two days less than for other groups and
their cumulative time hospitalized during the trial was significantly less than for
nonresponders or placebo groups (p<0.022). They also had the lowest doses of
parenteral opioids during acute care crises (p=.015).
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Introduction
Sickle cell anemia (SS) is a quadrumvirate of pain syndromes, anemia and its
sequelae, organ failure including infection, and co-morbid disorders.1-4 Pain, however,
is its predominant feature and the major complaint of patients throughout their life.5-9
Sickle cell pain can be of mild, moderate, or severe intensity and is usually sharp or
throbbing in nature, but can also be stabbing, deep, achy, lacerating, or shooting in
quality.5-9 Pain that is of mild or moderate intensity is usually treated at home with oral
or topical analgesics plus certain non-pharmacological modalities.5-9

Severe pain,

however, often requires emergency room and/or hospital in-patient treatment with
parenteral opioids. There are only rare multicenter randomized controlled trials that
compare the effect of drug treatment on the length of hospital stay for painful crises in
adult patients with SS.10,11 Anecdotes and reports from single institutions indicate the
duration of hospitalization for an uncomplicated painful crisis in adult patients varies
between 6 and 10 days.12-15
Nonopioid analgesics, adjuvants, topicals and oral opioids are often used during
hospitalization in addition to parenteral opioids. The amount of opioids required by
patients during hospitalization in order to achieve pain relief is often so high that it
concerns some providers who are not familiar with sickle cell disease and,
consequently, tend to under-treat patients with sickle cell pain. Some providers may
refuse to prescribe high doses of opioids during hospitalization and often accuse
patients of being malingerers, drug- seeking or even drug addicts.
To the best of our knowledge there are no multicenter randomized controlled
trials in the literature that describe the amount of opioids consumed by adult patients
with SS at home and during acute painful episodes that are treated as outpatients or
during hospitalization. Reports from single institutions described the utilization of
NSAIDs alone or in combination with certain opioids in a relatively small number of
hospitalized adult patients.16,17

Another small study compared the utilization of

parenteral butarphenol with morphine in adult patients in the emergency room.18 Other
reports addressed the factors that affect the quality of pain management in sickle cell
disease (SCD).19-21 The Multicenter Study of Hydroxyurea (MSH) in SS22 gave us an
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opportunity to report on this aspect of sickle cell disease. Although the original MSH
study showed that hydroxyurea decreased the frequency of painful crises that required
hospitalization, it did not address the duration of the painful crises or the amounts of
opioids used to control crisis pain during hospitalization, and it did not differentiate
between responders to HU and nonresponders. To that end, the goals of this paper are
to (1) determine the hospital length of stay (LOS) of adult patients with SS enrolled in
MSH 2) summarize the type and amount of opioids and other analgesics used by
patients at home and during acute painful crises, and (3) compare the LOS and opioid
utilization between the placebo and hydroxyurea treatment groups, and between
treatment responders and nonresponders within the hydroxyurea group.
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Methods
Patient characteristics
The methods of the MSH in SS have been described in detail elsewhere.22
Briefly, MSH participants had to be at least 18 years old, with a diagnosis of SS, and at
least 3 acute painful crises in the year prior to enrollment. A total of 299 patients were
enrolled from 21 sites (20 in the United States and 1 in Canada). There were no
significant differences between the hydroxyurea (HU) and placebo groups in terms of
sex, race, age, or blood counts at baseline. The sample included roughly equal
numbers of male (49%) and female (51%) patients, with an average age of 30 years
(range 18-59) at study entry.
Measures
Data on opioid use came from three sources: a “Patient Diary” form covering twoweek periods, completed daily at home by patients, and returned to clinical sites at
follow-up visits; a “Follow-Up Visit” form, completed by physicians at regular follow-up
visits every two weeks; and a “Medical Contact” form, completed by physicians
whenever a patient presented for any medical contact other than the regular follow-up
visits.
On the Patient Diary, patients indicated daily severity of pain and use of any
analgesic (but not the specific analgesic or dosage). The patient diaries were used to
determine overall frequency of at-home analgesic use.

Analgesic frequency was

defined as the proportion of all days on which patients reported using analgesics.

On the Follow-Up Visit form, physicians indicated use of any oral or transdermal
opioid since the last visit and the specific opioids used, the total dosage (in mg) since
the previous visit, and the number of days that the analgesic was taken. Physicians
could indicate one or more of six opioids directly listed on the form (meperidine,
oxycodone, morphine, hydromorphone, codeine, and the fentanyl patch) or write in
others. The four most common write-ins were coded for this analysis (methadone,
propoxyphene, levorphanol, and hydrocodone). The Follow-Up Visit form was used to

Analgesics 1 draft

1/11/2011

7

examine frequency of at-home analgesic use (as the proportion of all biweekly periods
in which patients reported analgesic use), multiple analgesic use, and frequencies and
dosages for specific analgesics.
On the Medical Contact forms, physicians indicated the location of each contact
(in-patient, emergency facility, MSH clinic, non-MSH clinic, doctor’s office, or ‘other’).
More than one choice could be marked if a single contact involved a visit to more than
one type of facility.

Physicians indicated use of specific analgesics from three

categories:

transdermal

oral

or

opioids

(meperidine,

oxycodone,

morphine,

hydromorphone, codeine, and the fentanyl patch), parenteral opioids (meperidine,
morphine, and hydromorphone), and non-steroidal anti-inflammatory agents (NSAIDs)
(Ketorolac). The most common write-in oral opioids (hydrocodone and methadone) and
parenteral opioids (nalbuphine and butorphanol) were also coded. Use of NSAIDs was
uncommon and no write-ins were coded. Physicians indicated the total dose (in mg) for
each medication and the number of days that medication was used.
Painful crises
Analysis of hospital length of stay (LOS) and of analgesic use during acute care
and in-patient contacts was restricted to contacts defined as sickle cell-related acute
painful crises under the criteria of the MSH clinical trial. In the trial, crises were defined
as visits to a medical facility that lasted more than four hours for acute sickling-related
pain, which was treated with a parenterally administered opioid (except for a few
facilities in which only orally administered opioids were used).22 Analyses were
restricted to painful crises in order to exclude medical contacts that might not be related
specifically to sickle cell pain or to other complications of the disease or comorbid
disorders.
Painful crises were divided into two categories: those involving in-patient
hospitalization and those involving only acute care facilities. If a crisis included inpatient hospitalization, regardless of contact with another type of facility, it was coded as
in-patient. If the crisis involved only an outpatient acute care facility (ER, MSH clinic,
non-MSH clinic, or doctor’s office), it was coded as acute care.
analyses, these categories were examined separately.

In all subsequent

The Medical Contact Form

Analgesics 1 draft

1/11/2011

8

provided data on the overall frequency of analgesic use, multiple analgesic use, and the
frequencies and dosages for specific analgesics, during painful crises.
Treatment group assignment and hydroxyurea response
Assignment to the HU or placebo group at study entry was a key predictor of
interest for analgesic usage. HU recipients were also divided into responder and
nonresponder groups, based on fetal hemoglobin (HbF) levels at baseline and at
approximately 18 months after initiation of treatment. A responder was defined as any
HU recipient whose baseline percentage of HbF was < 15%, but whose follow-up level
was >= 15%. This definition was based on previous research suggesting that 15% fetal
hemoglobin is a level expected to produce clinical benefits

23,24

, and this level is defined

by NHLBI treatment guidelines as a desired treatment outcome.25 Thus, an increase of
this magnitude in HbF could reasonably be expected to produce clinically salutary
benefits.
Statistical Methods
Types and dosages of at-home, acute care, and in-hospital analgesic usage
were explored descriptively. Frequencies of use for each analgesic were expressed in
three ways: as (1) percentages of all at-home periods, acute care crises, and in-patient
crises, (2) percentages of only those periods that involved analgesic use (for at-home
use only), and (3) percentages of the total number of analgesics used across all athome periods, acute care, and in-patient crises.

Equianalgesic doses were computed for each opioid, using standard formulas to
convert doses into morphine equivalents.6

For painful crises, total dosages for each

opioid were converted to morphine equivalents and summed to get a single total
dosage. Average daily doses were calculated by dividing the total dose by the number
of days that the crisis lasted. When the crisis duration was less than one day, the
number of days was set to one.
For at-home use, total dosages reported for each opioid on the Follow-up Visit
form were converted to equianalgesic doses and summed to get an overall total. To
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obtain daily averages, total doses were divided by the number of days of analgesic use
reported on the Patient Diary corresponding to that Follow-Up Visit form. Total days of
use were obtained from the Pain Diaries rather than the Follow-up Visit forms because
data for days of use were much more complete in the Diaries. Patient diaries and
Follow-Up Visit forms were matched using codes for visit number that appeared in the
data file for each form.
A check on data distribution indicated extreme non-normality (high skewness and
kurtosis) for variables related to equianalgesic dosing.

All equianalgesic dosing

variables were transformed using the natural logarithm to normalize data distributions.
The log-transformed values were used for group comparisons in the modeling described
below; least squares means (LSM) estimates from the models were exponentiated to
convert LSM estimates back into units of mg morphine equivalent. The same procedure
was used for data on the number and duration of painful crises.
The effects of treatment group and HU response on analgesic usage were
examined through between-group comparisons of (a) the proportion of all diary days
with analgesic use, (b) the occurrence of any analgesic use during at-home follow-ups,
acute care crises, and in-patient crises, (c) the total number of different analgesics
reported for each at-home follow-up, acute care, and in-patient painful crisis, (d) the
total (two-week) and average (daily) equianalgesic doses used at home, (e) the daily
equianalgesic doses used during acute care and in-patient painful crises; (f) cumulative
dosing across at-home follow-ups and painful crises for each patient; and (g) the
frequency, average duration, and cumulative duration of acute care and in-patient
painful crises.
Group differences in the proportion of diary days with analgesic use were tested
with linear regression models.

Differences in analgesic use at home and use of

parenteral and oral opioids and NSAIDs during painful crises were tested with RaoScott adjusted chi-square analyses (to control for multiple observations of each patient).
Total analgesics used during each at-home follow-up and painful crisis were compared
with Wilcoxon rank-sum tests with adjustment for clustering (to control for multiple
observations of each patient). Differences in average and cumulative equianalgesic
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dosing at home and during painful crises, and average and cumulative duration of
painful crises, were tested with repeated-measures linear mixed models.

Finally,

frequency of acute care and in-patient painful crises were modeled with zero-inflated
Poisson regression, due to large proportions of zeros and non-normality of the data.
Results were considered statistically significant if the associated p-value was ≤.05, and
‘marginally significant’ if .05<p≤ .10.
In light of the number of comparisons tested, the suggested thresholds for
statistical significance (p <.05) and marginal significance (0.05 < p <0.10) are intended
only as a rough non-conservative guideline for all the post hoc analyses performed in
this manuscript.
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Results
Type and frequency of analgesic use at home
Overall frequency. Patients’ average length of time in the MSH trial was 790
days (2.16 years). Based on the Patient Diaries, the mean and median percent of days
with analgesic use were 39.9% and 35.0%, respectively, with a range from almost 0% to
over 99% of all days. Of 16818 biweekly follow-up visits, oral opioid use was reported
in 59.9% (this does not imply analgesic use on all days of each two-week follow-up
period).
Frequency of individual analgesics. Table 1 lists the frequency of use for each
opioid as a percentage of (a) all biweekly follow-up visits (n=16818); (b) only those visits
for which opioid use was reported (n=10071); and (c) the total number of opioids
reported (the sum of separate opioids from follow-up form; n=11302). Oxycodone and
codeine were used most often, at 23% and 18% of all two-week follow-ups,
respectively. Together they accounted for 61.7% of all analgesics used and were at
least three times as frequent as the next most common opioids (meperidine and
hydromorphone).

Figure 1 displays frequency of use and mean dose (before

equianalgesic transformation) for each oral opioid at home.
Equianalgesic dosing.

The mean total dose during periods when analgesics

were used was 219.6 (SD=480.69) mg morphine equivalent; the median was 112.5 mg
morphine equivalent. For those days on which analgesics were used, the mean and
median daily doses were 25.1 (SD=40.79) and 15 mg morphine equivalent,
respectively. Because analgesics were typically not used every day, the average twoweek total is not simply a multiple of the average daily dose.
Relationship of treatment assignment and treatment response to at-home analgesic use
Frequency of at-home use. Based on Patient Diaries, placebo patients used
analgesics on 42.0% of all days, compared to 38.0% for hydroxyurea patients; however,
this difference was not statistically significant. The difference in use of any analgesic
during biweekly periods was also nonsignificant (58.8% for HU and 59.7% for placebo).
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There was no significant difference between treatment groups in the use of multiple
analgesics.
HU responders, however, used analgesics on significantly (p=.005) fewer days
(22.6%) than either nonresponders (42.2%) or placebo patients (42.0%).

HU

responders also used analgesics during significantly fewer two-week periods (40.8%)
than either nonresponders (63.3%) or placebo patients (59.7%), p=.006.

When

compared for use of multiple medications, responders used fewer than either
nonresponders or placebo patients (p<.0001).
Equianalgesic dosing during at-home use. Table 2 summarizes least squares
means (LSM) estimates from the mixed models of daily and two-week at-home dosing.
The HU and placebo groups did not significantly differ in average daily dosing at 11.3
and 11.5 mg morphine equivalent, respectively, p=.89. For two-week total doses, the
HU and placebo groups again did not significantly differ (p=.60).
For treatment response, average daily dosing for HU responders and
nonresponders did not differ, at 11.1 and 11.4 mg morphine equivalent, respectively
(p=.98).

For two-week total doses, the difference in mean values was again not

statistically significant (p=.18). However, the median value for two-week total dose is far
lower for responders (45 mg) than nonresponders (135 mg), reflecting use by
responders on significantly fewer days; variation in two-week totals was large (even
after log transformation) and may have prevented the group difference from reaching
significance.
Type and frequency of analgesic use during acute care (outpatient) contacts
Overall frequency.

There were 2249 acute care contacts, not leading to in-

patient hospitalization, that were defined as painful crises. Of these, 95.5% reported
treatment with parenteral opioids, 10.9% with oral opioids, and 9.2% with NSAIDs (the
three categories sum to more than the 100% because of multiple analgesic use by
some patients).
Frequency of individual analgesics.
analgesics during painful crises.

Table 3 shows frequency of use of

The most frequently used parenteral opioid was
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meperidine, at 69.3% of contacts; hydromorphone was second, at only 14.3% of
contacts. The most common oral opioid was oxycodone, at 3.9% of contacts. Figures 2
shows the percent of all acute care crises during which each parenteral opioid was
used.
Dosing. During acute care crises with analgesics use, mean and median daily
doses of parenteral opioids were 33.9 (SD=33.93) and 26 mg morphine equivalent,
respectively. For crises with oral opioid use, mean and median doses were 29.8 mg
(SD=45.23) and 15 mg morphine equivalent, respectively.
Relationship of treatment assignment/response to acute care analgesic use.
Frequency of acute care use. Placebo and HU patients did not differ in use of
parenteral opioids (p=.90), oral opioids (p=.60) or NSAIDs (p=.53).
HU responders were more likely than nonresponders or placebo patients to use
NSAIDs during outpatient acute care contacts (43.2% of contacts versus 6.6% and
10.0%, respectively), p<.0001; however, use of oral and parenteral opioids did not differ.
There were no differences in the total number of different analgesics used during
acute care painful crises, either between treatment groups (p=.90) or between treatment
response groups (p=.77).
Equianalgesic dosing during acute care painful crises.

Results of mixed

modeling for daily dosing are reported in Table 4. LSM estimates for treatment groups
did not significantly differ for either oral dosing (p=.18) or parenteral dosing (p=.93).
Response groups also did not significantly differ in either parenteral dosing (p=.41) or
oral dosing (p=.60).
Type and frequency of analgesic use during in-patient painful crises
Overall frequency.

There were 2209 painful crises involving in-patient

hospitalizations. Of these contacts, 96.4% reported use of parenteral opioids, 47.7%
oral opioids, and 11.3% NSAIDs.
Frequency of individual analgesics. Table 3 shows frequency of use for specific
analgesics during in-patient crises. The most frequently used parenteral opioid was
meperidine, at 75.3% of crises; morphine was second at 19.0%. The most common
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oral opioid was oxycodone (at 19.6% of in-patient crises), with all others less than half
as frequent. Figures 2 shows use of each parenteral opioids as a percent of all inpatient crises.
Medical inpatient contact dosing.

The mean and median daily doses of

parenteral opioids (when used) were 95.9 mg (SD=203.4) and 67 mg morphine
equivalent, respectively. For crises involving use of oral opioids, mean and median
doses were 75.2 mg (SD=182.93) and 40 mg morphine equivalent, respectively.
Relationship of treatment assignment /treatment response to in-patient analgesic use.
Frequency of hospital contact use. HU and placebo patients did not significantly
differ in use of parenteral opioids (p=.71), oral opioids (p=.57) or NSAIDs (p=.26).
Similarly, responders and nonresponders did not significantly differ in use of parenteral
opioids (p=.73), oral opioids (p=.64), or NSAIDs (p=.48). Finally, neither the treatment
groups nor the response groups differed in total analgesics used during in-patient
contacts, p=.75 and p=.84, respectively.
Equianalgesic dosing during in-patient painful crises. Mixed model results for
daily parenteral and oral dosing, by treatment and response groups, are reported in
Table 4. LSM estimates of dosing indicate nonsignificant differences between treatment
groups for both parenteral (p=.80) and oral (p=.96) use. There were also no significant
differences among HU responder, nonresponder, and placebo patients in estimates of
parenteral dosing (p=.71) or oral dosing (p=.43). Notably, median values for parenteral
and oral dosing, and to a lesser extent mean estimates for parenteral and oral dosing,
are higher for responders than nonresponders. Responders were both fewer in number
and had significantly fewer in-patient crises (see below) than nonresponders.
Differences in number and duration of acute care and in-patient painful crises.
Previously, it has been shown that HU patients in MSH had a significantly lower
rate of painful crises than did placebo patients22. We examined differences separately
for acute care and in-patient painful crises, and between HU responders and
nonresponders as well as treatment groups. Table 5 shows mean and median values
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for the numbers of acute care and in-patient painful crises by treatment group and
response group, and the mean and median duration of in-patient painful crises.
Number of in-patient and acute care crises. All models controlled for duration of
patients’ participation in the study.

There was a significant difference between

hydroxyurea and placebo groups in the number of in-patient painful crises (p=.0015),
with fewer crises for hydroxyurea patients than for placebo patients. When divided into
HU responders and nonresponders, differences were again significant (p<.0001), with
the HU responders having significantly fewer in-patient crises than the nonresponders.
Regression modeling also showed a significant difference between treatment groups in
the number of acute care crises (p<.0001) and between response groups as well
(p<.0001), with fewer crises for hydroxyurea patients compared placebo patients and for
responders compared to nonresponders.
Average duration of in-patient and acute care crises. When crises did occur,
there were no significant group differences in the average duration of those crises. For
in-patient crises, average duration did not significantly differ for either treatment groups
(p=.74) or response groups (p=.45); for acute-care crises, average duration also did not
differ between treatment (p=.76) or response (p=.96) groups. However, as shown in
Table 6, the average duration of in-patient crises was almost two days shorter for HU
responders than for either non-responders or placebo patients.
Cumulative duration of in-patient and acute care crises.

We also examined

cumulative duration of in-patient painful crises and acute care painful crises. For each
patient, we calculated the total amount of time spent hospitalized and in acute care by
separately summing the duration of all in-patient and acute-care crises for that patient.
The cumulative values were then transformed using the natural logarithm to normalize
the data. Mixed models were used to compare cumulative duration between treatment
groups and between response groups.
For treatment groups, there were no statistically significant differences in dosing
or duration for in-patient care.

There were marginally significant differences for

parenteral dosing during acute care (p=.10), with lower total doses for patients using
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HU, and for the cumulative duration of acute care crises (p=.095), with less cumulative
time for HU patients.
For response group comparisons, multiple significant differences emerged.
Table 6 shows mean and median values for cumulative dosing and cumulative duration,
by response groups. HU responders spent less cumulative time hospitalized (p=.022)
and less cumulative time in acute care (p=.015); they also had the lowest doses of
parenteral opioids during acute care crises (p=.015).

These differences emerged

despite extreme variation in the cumulative dosing and duration variables (see SDs in
Table 7); large numerical differences in other values (such as in-patient parenteral
dosing) may not have been statistically significant (even after log transformation) due in
part to the large SDs.
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Discussion
The insignia of sickle cell disease (SCD), in general, and sickle cell anemia (SS), in
particular, is the recurrent acute painful crisis that often requires admission to the
hospital through the emergency department and treatment with relatively large amounts
of opioids for a lengthy hospital stay that may last, in some patients, over one week. 6,2628

The duration of the acute sickle cell painful crisis and its management has been a

conundrum of confusion punctuated with assumptions, suspicions, stigmatization, faulty
accusations, under-treatment, occasionally over- treatment, barriers to quality
comprehensive care, and disparities. The acute sickle cell painful crisis is the most
common cause of hospitalization of patients with SS. Besides the acute and severe
pain, the crisis is often associated with other complications of the disease including,
among other thing, infection, acute chest syndrome, hyperhemolysis, and sudden
death.4,6,29-32 These serious complications associated with the painful crisis usually
manifest themselves within 1-5 days after hospital admission when discharge from the
hospital is imminent. The duration of the crisis and its management with opioids has
been a subject of controversy for a long time. Most insurance carriers approve regular
payments for the care of admitted patients with painful crises for 3 or 4 days unless a
longer hospital stay is justified. Panepinto et al.

33

found that the overall average of the

hospital length of stay in children with sickle cell painful crises was 4.4 days with older
children having longer LOS. Ellison and Bouchner

34

found that the unadjusted mean ±

SD of the LOS for the Medicaid children with SCD was 4.0 ±6.24 days compared to 3.0
± 5.22 for patients with private insurance. These 3 to 4 days of hospital LOS is often
applied to adult patients with SS pari passu. To that end patients may be discharged
prematurely and about 16% of discharged patients are readmitted within one week after
discharge and about 50% are readmitted within one month .35,36 Moreover, Davis et al.
analyzed National Inpatient Sample trends from 1989-1993, and found on average an
estimated 75,000 hospitalizations per year of SCD children and adults, with lengths of
stay less than 5 days for children and over 7 days for adults.37 Limiting the LOS per
diagnosis by Insurance carriers seems to encourage providers to discharge their
patients prematurely- a practice that is invariably associated with hospital readmission
within a short period after discharge 38 The MSH study gave us a great opportunity to fill
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the gap of knowledge pertinent to the LOS and the amount of opioid and non-opioid
analgesics consumed by patients with SS as outpatients and during hospitalization for
acute painful crises.
The MSH data showed that patients on HU are admitted less often to the hospital than
patients on placebo. Moreover, when patients who responded to HU are admitted to the
hospital for a painful crisis, the chances are that they will stay 2 days less than patients
not taking or not responding to HU. The reduction in the frequency of hospital
admissions and the shortened length of hospital stay amount to significant savings per
admission per patient as was described previously.39 Using 2009 charges, savings
amount to an estimated savings of about $27,000 per 7-day hospital admission per
patient. 40 Thus, besides its beneficial effects on morbidity and mortality 41due to SS, HU
has significant financial benefits. It is unfortunate that HU is underutilized
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in the

management of patients with SS in view of the potential savings to the institutions taking
care of patients with SCD and to Medical insurance providers.
The second important aspect of this study is that it provides important information about
the amount of opioid and non-opioid analgesics used by patients as outpatients and
during acute painful crises. At home patients with SS use opioid analgesics frequently
with oxycodone and codeine being the most commonly opioids used followed by
meperidine and hydromorphone. Patients reported in their diaries that they used opioids
about 40% of the time and some used them almost daily. This is similar to the data
reported in the PiSCES study.

8

The oxycodone used was the short-acting one,

because at the time of the trial in 1992-1995, the controlled release opioids (MScontin
and Oxycontin) were either not available or were not in common use. Patients who
responded to HU showed three significant differences in comparison to nonresponders
and placebo groups: 1) they used analgesics on fewer days at home; 2) they used
analgesics during fewer of two-week follow-up periods; and 3) they used multiple
medications less often than the other two groups. These findings suggest that HU
seems to ameliorate the severity of painful episodes that occur at home.
HU, however, did not affect the use of any analgesic category during acute painful
episodes treated as outpatients in the emergency department, clinic, medical office or
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day unit. Responders to HU were more likely than nonresponders and placebo groups
to use NSAIDs during these crises, but there was no difference in the use of parenteral
or oral opioids. Again this may suggest that the pain intensity in these crises seems to
be slightly milder in responders in comparison to nonresponders.
As was reported previously

22

, HU decreased the frequency of painful crises by

about 50%. The decrease in responders is even more impressive and amounts to about
75% reduction in the number of painful crises that require hospital admission. Moreover,
the hospital length of stay is about 2 days shorter than nonresponders or placebo
groups.

The average daily amount of opioids used by the placebo group during

hospitalization, however, is not significantly different from the responder and
nonresponder groups. This suggests that the severity of painful crises during
hospitalization seems to be the same during the initial days of the crisis in the placebo
and HU groups. Responders may have been hospitalized only for the most severe
crises while nonresponders were hospitalized more often and their hospitalizations may
have included many milder crises. Since responders to HU are admitted to the hospital
less frequently and their length of stay is about 2 days shorter per admission, the
cumulative amount of opioids responders utilize over time is much smaller than that
consumed by the placebo and nonresponder groups. The advantages of this reduction
are not only financial but include the reduction of side effects associated with long term
use of opioids including, among other things, tolerance, dependence and hyperalgesia.
Thus HU decreases the frequency of hospital admissions due to crises, shortens their
duration, decreases the frequency of acute chest syndromes

and reduces the net

amount of opioids utililized during hospitalization. Moreover, should hydroxyurea be
approved for use in children the medical and financial benefits would be substantial.
Another aspect of this study that should be addressed pertains to the high utilization of
meperidine during MSH. This was the drug of choice between the 1960’s and 1990’s
and the preferred opioid by the majority of patients. One of the reasons is that the FDA
approved meperidine for the treatment of severe pain in November 1942, whereas,
morphine sulphate was approved in January 1984. The decline in the utilization of
meperidine is due to the epileptogenic effect of normeperidine, its major metabolite. The
use of meperidine for the treatment of sickle cell painful crisis continues to be
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controversial.42-44 There is consensus at the present that meperidine should not be used
in patients with history of seizure or in the presence of renal impairment. The reported
incidence of seizures due to meperidine varies between 1 to 12 %.

45,46

The

disadvantages for morphine are that its utilization in patients with SCD seems to be
associated with acute chest syndrome

47-48

and that it induces kidney injury in the

transgenic sickle cell mouse.49 The increase in acute chest syndrome could be
incidental due to increased awareness among providers of the severity of pulmonary
complications of SCD. Whether the advent of morphine sulphate has anything to do with
this increase remains to be determined.

In Conclusion this study shows that the beneficial effects of treating sickle cell anemia
with hydroxyurea include shortening the duration of hospitalization due to acute painful
episodes and reducing the net amount of opioid utilization during hospitalization in
addition to its known effects of reducing the frequency of hospital admissions due to
crises,22 reducing the frequency of acute chest syndrome,22 improving the quality of
life50 and decreasing morbidity & mortality.41,51
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Tables
Table 1.
Frequency of at-home opioid use
Opioid
Frequency
(listed in order of
% of all diaries
frequency)
(n=16818)

Mean daily dose,
Median daily dose,
% of diaries with
b
b
a
mg (SD)
mg
any opioid use
(n=10071)
Any opioid
59.9
100.0
NA
NA
Oxycodone
23.2
39.1
15.5 (9.65)
12.3
Codeine
18.3
31.0
79.8 (77.24)
60.0
Meperidine
6.7
11.4
186.7 (190.70)
118.3
Hydromorphone
6.6
11.2
7.1 (5.21)
4.4
Hydrocodone
5.4
9.0
22.6 (18.98)
16.4
Morphine
3.3
5.6
40.2 (25.57)
30.0
Methadone
1.4
2.3
17.2 (10.34)
20.0
Propoxyphene
0.9
1.6
163.6 (79.15)
133.3
a
Totals in this column sum to more than 100% due to multiple medication use at some visits.
b
mg=milligrams, SD=Standard deviation. Values in these columns are the original dosage of each
opioid, not the transformed equianalgesic dosages.
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Table 2.
Equianalgesic dosing (mg morphine equivalent), at-home periods with any analgesic use
a
Means(standard error)
Medians
Two-week total Average daily
Two-week total Average daily
dose
dose
dose
dose
Treatment group
Hydroxyurea (n=152)
59.7 (1.11)
11.3 (1.08)
114.0
15.0
Placebo (n=147)
64.4 (1.11)
11.5 (1.08)
112.5
15.0
HU response group
Responders (n=27)
43.4 (1.28)
11.1 (1.21)
45.0
13.2
Nonresponders (n=116)
62.7 (1.12)
11.4 (1.09)
135.0
15.6
a
Derived from least squares means (LSM) estimates in mixed models of log-transformed data. All values
expressed as mg morphine equivalent.
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Table 3.
Frequency and dosage in mg of opioid and NSAID use during painful crises
Daily dose
Daily dose
% of all inDaily dose
Daily dose
Analgesic
% of all acute
a
a
during in-patient during in-patient
patient contacts
during acute
during acute
care contacts
b
crises, median
crises, mean
(n=2209)
care crises,
care crises,
(n=2249)
b
b
b
(SD)
median
mean (SD)
Parenteral (any):
95.5
NA
NA
96.4
NA
NA
Meperidine
69.3
248.4 (145.70)
225
75.3
523.4 (382.40)
463
Hydromorphone
14.3
12.5 (9.26)
12
15.6
30.2 (65.26)
19
Morphine
8.9
18.8 (20.85)
14
19.0
53.3 (110.82)
30
Butorphanol
2.3
7.5 (4.81)
8
1.0
10.4 (12.45)
5
Nalbuphine
3.3
40.4 (14.84)
40
0.7
45.1 (23.3)
40
Oral (any):
10.9
NA
NA
47.7
NA
NA
Oxycodone
3.9
14.1 (11.34)
10
19.6
28.2 (23.47)
25
Meperidine
2.5
248.7 (311.52)
175
8.6
415.4 (303.22)
371
Hydromorphone
2.2
8.3 (4.80)
8
8.0
27.6 (96.73)
8
Morphine
1.1
62.0 (59.36)
60
7.9
143.1 (158.15)
90
Codeine
1.2
69.7 (43.94)
60
7.7
113.3 (72.82)
90
Hydrocodone
0.3
14.9 (11.73)
10
1.7
57.6 (182.41)
14
Methadone
0.5
27.4 (9.68)
30
1.6
39.3 (41.26)
28
a
Totals for individual analgesics in a category sum to more than the category total due to multiple analgesic use at some contacts.
b
Original doses of each drug (prior to conversion into mg morphine equivalent)
NA=Not applicable.
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Table 4.
Daily equianalgesic dosing during acute care (outpatient) painful crises
a
Means (standard error)
Medians
Average daily
Average daily
Median daily
Median daily
parenteral dose
oral dose
parenteral dose
oral dose
Treatment group
Hydroxyurea (n=152)
22.8 (1.07)
19.1 (1.10)
39.0
15.0
Placebo (n=147)
22.6 (1.06)
22.7 (1.09)
32.5
18.0
HU response group
Responders (n=27)
17.7 (1.23)
16.0 (2.23)
13.0
16.0
Nonresponders (n=116)
23.5 (1.07)
20.2 (1.11)
39.0
16.0
a
Derived from least squares means (LSM) estimates in mixed models of log-transformed data. All values expressed as mg morphine equivalent.
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Table 5.
Daily equianalgesic dosing, in-patient painful crises
a
Means (standard error)
Medians
Average daily
Average daily
Median daily
Median daily
parenteral dose
oral dose
parenteral dose
oral dose
Treatment group
Hydroxyurea (n=152)
42.7 (1.11)
34.0 (1.10)
74.8
42.0
Placebo (n=147)
41.3 (1.10)
34.2 (1.09)
63.6
43.3
HU response group
Responders (n=27)
54.8 (1.40)
50.5 (1.38)
112.0
193.0
Nonresponders (n=116)
42.3 (1.12)
32.6 (1.10)
75.7
40.0
a
Derived from least squares means (LSM) estimates in mixed models of log-transformed data. All values expressed as mg morphine equivalent.
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Table 6
Number and duration of acute care and in-patient painful crises
Number of acute
Number of incare crises
patient crises
Treatment group
Mean (SD),
Mean (SD),
median
median
Hydroxyurea (n=152)
6.6 (17.3), 2
6.4 (8.5), 3
Placebo (n=147)
8.5 (16.7), 2
8.5 (10.1), 5
HU response group
Responders (n=27)
1.4 (2.9), 1
2.1 (4.1), 0
Nonresponders (n=116)
7.8 (19.4), 2
7.2 (8.8), 4
SD=Standard deviation, LOS=length of stay (in days).
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LOS, in-patient
crises
Mean (SD),
median
7.6 (6.7), 6.0
7.8 (6.5), 6.2
5.9 (2.6), 5.5
7.7 (6.8), 6.0
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Table 7.
Cumulative equianalgesic dosing and duration: means (SDs) by response group
In-patient crises (n=2209)
Acute care crises (n=2409)
HU response
Cumulative
Cumulative
Cumulative
Cumulative
Cumulative
group
oral dose in
parenteral
duration in
oral dose in
parenteral
mg:
dose in mg:
days:
mg:
dose in mg:
mean (SD)
mean (SD)
mean (SD)
mean (SD)
mean (SD)
Responders
1114 (2770.4)
730 (2716.3)
12.4 (24.8)
35 (96.0)
0.6 (3.1)
(n=27)
Nonresponders
3848 (9187.9)
736 (2624.6)
55.3 (75.1)
391 (1447.6)
26.6 (77.6)
(n=116)
Placebo
4897 (15990.1) 1155 (5303.0)
66.2 (94.4)
459 (1203.6)
68.2 (256.2)
(n=147)
SD=Standard deviation, mg=mg morphine equivalent

Cumulative
duration in
hours:
mean (SD)
27 (86.9)
108 (218.7)
133 (260.9)
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Figure Legends

Figure 1. Utilization of oral opioids at home
Figure 2. Parenteral opioid utilization by crisis location
Figure 3. Oral opioid utilization by crisis location
Figure 4. Utilization of parenteral opioids in in-patient crises
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